ABEOAbeona Therapeutics Inc.
Abeona Therapeutics (ABEO) sells gene therapy treatments for rare genetic disorders, with its lead product ZEVASKYN targeting Sanfilippo syndrome. The next catalyst is Sep 22, 2026 — Anticipated Equity Financing, which will test the company’s ability to raise capital amid a cash burn and uncertain commercial momentum.
- Revenue surged 66.3% YoY to $20.90M in Q2 2026, but free cash flow remains negative at -$166.14M TTM.
- Net margin hit 317.7% TTM, driven by losses offset by non-cash items, but net income was still -$66.41M.
- Debt-to-equity ratio is low at 0.13x, but cash flow is a drag on growth.
The Read
Abeona Therapeutics’ stock declined about 7% after Q4 2025 earnings as initial ZEVASKYN revenue was minimal despite launch momentum and strong cash, then fell over 10% post-Q1 2026 as early patient treatments and network expansion failed to impress amid a strategic shift away from ophthalmology.
The schedule
- Wed11Nov
This news event could provide additional insight into the company's strategic direction, clinical progress, or financial health, potentially influencing investor sentiment.
- Thu12Nov
This earnings report will test the company's ability to maintain revenue growth and manage its cash flow amid ongoing regulatory and legal challenges. The outcome will also provide insight into the progress of its key therapeutic candidates.
- Sat9Jan
The resubmission of the BLA for UX111 will test the company's ability to address any deficiencies in its regulatory submission and secure approval for the treatment of MPS IIIA.
- Sun14Feb
- Wed12May
- Thu12Aug
Past
- Fri25Sep
Actual outcome: Bear · $4.95 at outcome
The stock fell 6.8% from the event date to the outcome date, reflecting negative market sentiment. The event likely failed to meet investor expectations, with potential factors such as underwhelming earnings, weak guidance, or unfavorable news overshadowing any positive developments. The price movement suggests the market reacted to these factors, moving away from the bull case and aligning with the bear scenario.
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
- Tue22Sep
Actual outcome: Bear · $5.16 at outcome
The stock fell 11.5% following the equity financing announcement, indicating investor concern over the dilution risk and lack of confidence in the company's capital raising ability. The price closed below the bear floor of $5.00, reinforcing the bearish outcome. The equity financing event did not provide positive catalysts to offset the negative sentiment, and the stock continued to trade lower even after the event date.
The anticipated equity financing could test the company's ability to raise capital without diluting existing shareholders, while also signaling confidence in its future prospects.
- Thu13Aug
Actual outcome: Bear · $6.13 at outcome
Abeona reported Q2 revenues of $11.4 million, missing analyst expectations despite meeting EPS estimates of -$0.30. The company disclosed operational setbacks in the ZEVASKYN rollout, including patient scheduling cancellations and manufacturing issues that affected revenue recognition, which drove the stock lower as investors priced in a steeper learning curve for the commercial launch.
Q2 2026 earnings focusing on the ZEVASKYN commercial ramp and cash runway attrition.
- Mon1Jun
Abeona Therapeutics (NASDAQ: ABEO) Upcoming PDUFA Date on ...
- Wed13May
Actual outcome: Bear · $5.14 at outcome
Abeona Therapeutics met Q1 EPS estimates of -$0.39 and reported early commercial momentum for ZEVASKYN, including three patients treated and an expansion of its treatment center network. However, the stock fell 10.3% and breached the bear floor, as the market likely viewed the initial launch metrics as underwhelming and reacted cautiously to the company's strategic shift to deprioritize its ophthalmology programs in favor of a newly licensed solid tumor technology.
Abeona reports Q1 earnings, with the market intensely focused on the commercial velocity of ZEVASKYN following a disappointing Q4 where only a single patient was treated.
- Tue17Mar
Actual outcome: Bear · $4.33 at outcome
Abeona met EPS estimates, but the stock fell below the bear floor as the report of only one commercial ZEVASKYN patient treated by year-end suggested a slower-than-anticipated commercial ramp. Despite a strong cash position and management's narrative of 'building momentum,' the market reacted negatively to the modest initial
First full quarter of commercial data for ZEVASKYN (pz-cel) in RDEB.
